Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.81 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.67 |
| ▸ | CCR8 | P51685 | 2/20 | 0.64 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034921 | 0.91 | MCHR1 (0.77) | SIGMAR1MCHR1CCR8 | |
| SCHEMBL6497533 | 0.89 | CCR8 (0.81) | SIGMAR1CCR8 | |
| SCHEMBL4034536 | 0.84 | MCHR1 (0.65) | SIGMAR1MCHR1 | |
| SCHEMBL17951031 | 0.83 | MCHR1 (0.68) | SIGMAR1MCHR1 | |
| SCHEMBL4032073 | 0.82 | SIGMAR1 (0.79) | SIGMAR1MCHR1CCR8ACKR3 | |
| SCHEMBL4032982 | 0.82 | MCHR1 (0.62) | SIGMAR1MCHR1 | |
| SCHEMBL4032985 | 0.82 | MCHR1 (0.62) | SIGMAR1MCHR1 | |
| SCHEMBL3135058 | 0.81 | SIGMAR1 (0.67) | SIGMAR1MCHR1 | |
| SCHEMBL4033889 | 0.81 | MCHR1 (0.58) | SIGMAR1MCHR1ACKR3 | |
| SCHEMBL4034602 | 0.81 | SIGMAR1 (0.83) | SIGMAR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | MERRILL LYNCH CAPITAL, A DIVISION OF MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC. AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | CXCR4, CXCR1, CXCR3 | SIGMAR1 126/4885MCHR1 408/4885CCR8 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.